BioXcel Therapeutics names interim CCO amid IGALMI expansion

Bioxcel Therapeutics ( (BTAI) ) has shared an update.

On January 12, 2026, BioXcel Therapeutics announced the appointment of Mark Pavao as Interim Chief Commercial Officer to support the potential launch of its drug IGALMI for at-home use. The company plans to submit a supplemental New Drug Application this month seeking FDA approval to expand IGALMI’s indication to at-home treatment of acute agitation in patients with bipolar disorders or schizophrenia, a move that could significantly broaden its commercial reach and influence treatment practices for managing psychiatric agitation outside institutional settings.

The most recent analyst rating on (BTAI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.

Spark’s Take on BTAI Stock

According to Spark, TipRanks’ AI Analyst, BTAI is a Neutral.

The score is held down primarily by weak financial performance (minimal/declining TTM revenue, large losses, heavy cash burn, negative equity, and high debt vs. assets). Technicals are mixed with some near-term strength but a weaker longer-term trend, while valuation is difficult to support given negative earnings. Positive clinical/regulatory-related updates provide some offset but do not outweigh the financial risk.

To see Spark’s full report on BTAI stock, click here.

More about Bioxcel Therapeutics

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for neuropsychiatric conditions, including agitation associated with bipolar disorders and schizophrenia, with its drug IGALMI as a key product candidate in this space.

Average Trading Volume: 667,360

Technical Sentiment Signal: Sell

Current Market Cap: $43.74M

For detailed information about BTAI stock, go to TipRanks’ Stock Analysis page.